Across the recent three months, 4 analysts have shared their insights on Editas Medicine (NASDAQ:EDIT), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
3
0
0
Last 30D
0
0
1
0
0
1M Ago
1
0
2
0
0
2M Ago
0
0
0
0
0
3M Ago
0
0
0
0
0
Analysts have set 12-month price targets for Editas Medicine, revealing an average target of $9.5, a high estimate of $15.00, and a low estimate of $7.00. Highlighting a 32.14% decrease, the current average has fallen from the previous average price target of $14.00.
Investigating Analyst Ratings: An Elaborate Study
The standing of Editas Medicine among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Liisa Bayko
Evercore ISI Group
Lowers
In-Line
$7.00
$15.00
Samantha Semenkow
Citigroup
Lowers
Buy
$15.00
$16.00
Matthew Harrison
Morgan Stanley
Announces
Equal-Weight
$7.00
-
Gena Wang
Barclays
Lowers
Equal-Weight
$9.00
$11.00
Key Insights:
Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Editas Medicine. This information offers a snapshot of how analysts perceive the current state of the company.
Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning ...Full story available on Benzinga.com
Benzinga
Beam Therapeutics Inc.
CRISPR Therapeutics AG
Intellia Therapeutics, Inc